首页> 外文期刊>The Journal of hospital infection >Use of palivizumab and infection control measures to control an outbreak of respiratory syncytial virus in a neonatal intensive care unit confirmed by real-time polymerase chain reaction.
【24h】

Use of palivizumab and infection control measures to control an outbreak of respiratory syncytial virus in a neonatal intensive care unit confirmed by real-time polymerase chain reaction.

机译:通过实时聚合酶链反应证实,使用帕利珠单抗和感染控制措施可控制新生儿重症监护病房中呼吸道合胞病毒的爆发。

获取原文
获取原文并翻译 | 示例
           

摘要

Respiratory syncytial virus (RSV) is a potentially life-threatening infection in premature infants. We report an outbreak involving four infants in the neonatal intensive care unit (NICU) of our hospital that occurred in February 2010. RSV A infection was confirmed by real-time polymerase chain reaction. Palivizumab was administered to all infants in the NICU. There were no additional symptomatic cases and repeat RSV surveillance confirmed that there was no further cross-transmission within the unit. The outbreak highlighted the infection control challenge of very high bed occupancy in the unit and the usefulness of molecular methods in facilitating detection and management.
机译:呼吸道合胞病毒(RSV)在早产儿中可能威胁生命。我们报告了2010年2月发生在我院新生儿重症监护室(NICU)的一次暴发,涉及4名婴儿。RSV A感染已通过实时聚合酶链反应确认。对新生儿重症监护病房(NICU)的所有婴儿均给予帕利珠单抗治疗。没有其他有症状的病例,重复进行RSV监测证实单位内没有进一步的交叉传播。疫情突出说明了该病床中床位占用率很高的感染控制挑战,以及分子方法在促进检测和管理中的实用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号